Avalanche Biotechnologies (AAVL) Tops Q2 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq ends down as chipmakers fall and bank earnings roll in
- Oil prices settle mixed, focus on US-Russia diesel deal, Saudi Yemen attacks
- JPMorgan shares edge lower after third-quarter FICC revenue miss
- Fed’s Waller says US bond yield rise driven by growth, not inflation
- Wells Fargo beats profit estimates despite revenue miss
Tweet
Share
E-mailGet Alerts AAVL Hot Sheet
Join SI Premium – FREE
Avalanche Biotechnologies (NASDAQ: AAVL) reported Q2 EPS of ($0.38), $0.01 better than the analyst estimate of ($0.39). Revenue for the quarter came in at $203 thousand versus the consensus estimate of $760 thousand.
For earnings history and earnings-related data on Avalanche Biotechnologies (AAVL) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman’s CEO Solomon says to watch political volatility around data centers
- Freedom Broker Downgrades Taylor Devices, Inc. (TAYD) to Hold
- Top rail stocks to watch according to Jefferies analysis
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
